HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China
单位：[1]Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunologic Liver Disease, Beijing, China[2]Yamanashi Prefectural Hospital Organization, Yamanashi, Japan[3]Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea[4]Shanghai Jiaotong University Ruijin Hospital, Shanghai, China[5]Nanfang Hospital of Southern Medical University, Guangzhou, China[6]Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China首都医科大学附属北京友谊医院[7]Gilead Sciences, Inc, Foster City, CA, USA[8]Yonsei University College of Medicine Seoul, South Korea[9]Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan[10]Beijing Youan Hospital Affiliated to Capital Medical University, Beijing, China
Background & aims: Resistance associated substitutions (RAS) can reduce the efficacy of some direct-acting antiviral HCV regimens. Here, prevalence of RAS in genotype (GT) 1b, 2, 3, and 6 HCV-infected patients from Asian counties, North America and Europe are described and compared. Methods: Pretreatment HCV RAS were assessed with 15% cutoff from patients enrolled in clinical trials of sofosbuvir-containing regimens in Mainland China, Japan, Korea, and India. Phylogenetic analyses were performed to investigating subtype diversity. Results: In GT1b patients, the prevalence of NS5A RAS, including Y93H, was similar across Asian countries (18-21%), and North America (15%) or Europe (19%). The prevalence of NS5B NI RAS, including L159F, was lower in Asian countries (1-5%) compared to North America (4%) or Europe (20%). The prevalence of NS3 RAS in patients from China (22%) and North America (28%) were lower than in Europe (40%). For GT2 patients in China, 100% had GT2a subtype with high prevalence of NS5A L31M. For GT3, the prevalence of GT3b was substantially higher in China (54%) than in North America or Europe (< 1%); 99% of GT3b patients in China had NS5A RAS A30K + L31M, which confers high levels of resistance to NS5A inhibitors. In GT3a patients in China, the prevalence of NS5A RAS was lower (5%) than in North America and Europe (14-16%). Prevalence of NS5B NI RAS in GT2 and GT3 patients was rare across regions (< 2%). Conclusions: Differences in the prevalence of GT2 and GT3 subtypes and NS5A RAS were observed between Asian and Western countries.
第一作者单位：[1]Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunologic Liver Disease, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Wei Lai,Omata Masao,Lim Young-Suk,et al.HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China[J].ANTIVIRAL RESEARCH.2018,158:178-184.doi:10.1016/j.antiviral.2018.08.001.
APA：
Wei, Lai,Omata, Masao,Lim, Young-Suk,Xie, Qing,Hou, Jin Lin...&Duan, Zhongping.(2018).HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.ANTIVIRAL RESEARCH,158,
MLA：
Wei, Lai,et al."HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China".ANTIVIRAL RESEARCH 158.(2018):178-184
